retatrutide phase 3 Severe Obesity Trial Shows 30% Weight Loss 🚨 HOT OFF THE PRESS:

Every patient responds differently, but many people are looking for a steadier and more manageable approach than traditional higher-dose protocols

Mechanism and Indications: Same Biology, Different Goals GLP-1 receptor agonists function through a well-characterized physiological pathway

Should I take health advice from a board-certified obese doctor or from my father, a bike mechanic with no college degree, who is fitter in his 70s than most people are in their 30s

PubChem CID: 56843331

Suspected adverse effects should be reported via the MHRA Yellow Card Scheme

NCT06015893 Semaglutide Therapy for Alcohol Reduction (STAR) Status: Recruiting This study will test the safety/tolerability and early efficacy of subcutaneous (s.c.) semaglutide at the dose of 2.4 mg/week or maximum tolerated dose (MTD) as a potential new treatment for alcohol use disorder (AUD)